Editas Medicine Inc. share price logo

Editas Medicine Inc. Share Price

NASDAQ: EDIT

Small Cap

$2.73

-0.10

(-3.71%)

as on

Editas Medicine Inc. Stock Performance

as on September 18, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $2.71
    $2.9
    downward going graph

    0.73%

    Downside

    6.23%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.91
    $4.12
    downward going graph

    66.66%

    Downside

    50.92%

    Upside

    downward going graph

Editas Medicine Inc. share price movements today

Previous Close
$2.83
Open
$2.81
Volume
1.4M
Day's Low - High
$2.71 - $2.9
52 Week Low - High
$0.91 - $4.12

Editas Medicine Inc. Historical Returns

1 Month Return
-6.6 %
3 Month Return
+ 32.24 %
1 Year Return
-26.68 %
3 Year Return
-80.39 %
5 Year Return
-91.35 %

Editas Medicine Inc. Stock Fundamentals & Key Indicators

Check Editas Medicine Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$240.1M

EPS (TTM)

-1.9993

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.58

Industry PE ratio

-3.9281873111782475

P/B Ratio

0

PEG Ratio

0

EBITDA

-154.1M

Revenue (TTM)

38.9M

Profit Margin

0.00%

Return On Equity TTM

47771700.00%

Editas Medicine Inc. Stock Valuation

Track how Editas Medicine Inc. P/E has moved over time to understand its valuation trends.

Editas Medicine Inc. in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 17, 2025

Industry (-3.93x)

September 17, 2025

Today (-1.58x)

September 17, 2025

Highest (-0.48x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.58x

Editas Medicine Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Editas Medicine Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$240.1M-91.35%-1.580.00%
BUY$60.5B252.04%-505.15-12.96%
NA$39.0BNANA-3.89%
BUY$100.3B44.17%27.8531.86%
BUY$59.6B1.78%14.131.37%

Stock Returns calculator for Editas Medicine Inc. Stock including INR - Dollar returns

The Editas Medicine Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Editas Medicine Inc. investment value today

Current value as on today

₹75,324

Returns

₹24,676

(-24.68%)

Returns from Editas Medicine Inc. Stock

₹29,275 (-29.27%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Editas Medicine Inc. Stock

Based on 24 analysts

BUY

54.17%

Buy

41.67%

Hold

4.17%

Sell

Based on 24 analysts, 54.17% of analysts recommend a 'BUY' rating for Editas Medicine Inc.. Average target price of $4

Editas Medicine Inc. Share Price Target

Get share price movements and forecasts by analysts on Editas Medicine Inc..

What analysts predicted

31.75%UPSIDE

Target Price

$4

Current Price

$2.73

Analyzed by

24 Analysts

Target

$4.00

Editas Medicine Inc. target price $4, a slight upside of 31.75% compared to current price of $2.73. According to 24 analysts rating.

Editas Medicine Inc. Stock's Interest Amongst Investors

Search interest for Editas Medicine Inc. Stock has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-32% versus previous 30 day period

Editas Medicine Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
9
2
5
60
1
0
0
30
4
3
Gross Profit
8
1
3
58
0
0
-1
29
4
3
Operating Income
-50
-44
-50
-23
-66
-71
-65
-46
-76
-51
EBITDA
-49
-42
-48
-22
-65
-70
-60
-44
-71
-49
Interest Expense
3
-
-
3
-
-
-
-
2
2
Depreciation
1
1
1
1
1
1
1
1
1
1
Income Before Tax
-49
-40
-45
-18
-61
-67
-62
-45
-76
-53
Income Tax Expense
-3
-5
-1
10
0
-
1
-
-
-
Net Income
-45
-40
-45
-18
-61
-67
-62
-45
-76
-53
Net Profit Margin
-462.56%
-1395.57%
-843.68%
-31.43%
-5458.15%
-13178.75%
-101870.49%
-148.33%
-1633.49%
-1487.84%

Editas Medicine Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
1
6
13
31
20
90
25
19
78
32
Gross Profit
-17
-50
-69
-58
-76
90
25
19
72
26
Operating Income
-35
-97
-119
-113
-140
-134
-193
-225
-169
-238
EBITDA
-72
-96
-116
-110
-138
-130
-188
-219
-163
-233
Interest Expense
0
0
0
3
7
2
5
4
-
-
Depreciation
-
-
2
3
2
3
5
6
6
5
Income Before Tax
-72
-97
-120
-109
-133
-115
-192
-220
-153
-237
Income Tax Expense
-37
-1
-1
-3
-10
-6
-7
-16
5
-
Net Income
-72
-97
-120
-109
-133
-109
-185
-204
-153
-237
Net Profit Margin
-4475.14%
-1605.53%
-876.49%
-344.28%
-651.43%
-120.59%
-724.66%
-1036.69%
-196.13%
-733.72%

Editas Medicine Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-40
-45
-18
-61
-67
-62
-45
-76
-53
Operating Cash Flow
-38
-35
-22
-49
-57
-52
-50
-47
-50
Investing Cash Flow
12
-102
62
-4
51
83
30
56
42
Financing Cash Flow
117
-
0
0
0
-
55
-1
7
Change in Cash
91
-138
41
-54
-4
31
35
7
0

Editas Medicine Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-97
-120
-109
-133
-115
-192
-220
-153
-237
Operating Cash Flow
-49
-9
-45
-40
-179
-163
-177
-132
-210
Investing Cash Flow
-5
-183
-53
12
-140
-54
114
-3
162
Financing Cash Flow
97
154
86
131
224
282
1
118
56
Change in Cash
42
-38
-11
103
-96
63
-61
-17
7

Global Institutional Holdings in Editas Medicine Inc.

Funds
Holdings
Vanguard Group Inc
8.92%
BlackRock Inc
7.99%
Morgan Stanley - Brokerage Accounts
3.18%
UBS Asset Mgmt Americas Inc
3.11%
Geode Capital Management, LLC
2.32%

Insights on Editas Medicine Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, EDIT stock has moved up by 10.5%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -76.08M → -53.23M (in $), with an average increase of 42.9% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.1% return, outperforming this stock by 94.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 196.9%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 30.60M → 3.57M (in $), with an average decrease of 54.0% per quarter

About Editas Medicine Inc.

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
OrganisationEditas Medicine Inc.
Headquarters11 Hurley Street, Cambridge, MA, United States, 02141
IndustryHealth Technology
CEODr. Gilmore O'Neill M.D.
E-voting on sharesClick here to vote

Key Management of Editas Medicine Inc.

Name

Title

Dr. Gilmore O'Neill M.D.

President, CEO & Director

Dr. George McDonald Church Ph.D.

Co-Founder & Scientific Advisory Board Member

Ms. Amy Parison

Senior VP & CFO

Dr. Linda C. Burkly Ph.D.

Executive VP & Chief Scientific Officer

Ms. Linea Aspesi

Executive VP & Chief Administration Officer

Mr. Damien Grierson J.D.

Senior VP, General Counsel & Corporate Secretary

Dr. Feng Zhang Ph.D.

Co-Founder & Scientific Advisory Board Member

Mr. Gregory Whitehead

Executive VP and Chief Technical & Quality Officer

Cristi Barnett

Senior VP of Corporate Communications & Investor Relations

Mr. Frank Panaccio

Senior VP & Chief Business Officer

FAQs

What is Editas Medicine Inc. share price today?

Editas Medicine Inc. share price today is $2.73 as on at the close of the market. Editas Medicine Inc. share today touched a day high of $2.9 and a low of $2.71.

What is the 52 week high and 52 week low for Editas Medicine Inc. share?

Editas Medicine Inc. share touched a 52 week high of $4.12 on and a 52 week low of $0.91 on . Editas Medicine Inc. stock price today i.e. is closed at $2.73,which is 33.74% down from its 52 week high and 199.97% up from its 52 week low.

What is Editas Medicine Inc.'s market capitalisation today?

Editas Medicine Inc. market capitalisation is $0.00T as on .

How to invest in Editas Medicine Inc. Stock (EDIT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Editas Medicine Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Editas Medicine Inc. Shares that will get you 0.5495 shares as per Editas Medicine Inc. share price of $2.73 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Editas Medicine Inc. Stock (EDIT) from India?

Indian investors can start investing in Editas Medicine Inc. (EDIT) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Editas Medicine Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Editas Medicine Inc. share’s latest price of $2.73 as on September 18, 2025 at 1:29 am IST, you will get 3.6630 shares of Editas Medicine Inc.. Learn more about fractional shares .

What are the returns that Editas Medicine Inc. has given to Indian investors in the last 5 years?

Editas Medicine Inc. stock has given -91.35% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?